Healthcare Industry News: Vertex Pharmaceuticals
News Release - June 15, 2021
Senda Biosciences Strengthens Leadership Team with Key Management HiresCAMBRIDGE, Mass., June 15, 2021 -- (Healthcare Sales & Marketing Network) -- Senda Biosciences, Inc., a biotechnology company harnessing the molecular interactions between humans, plants and bacteria to enable new types of medicines, today announced the appointments of Matthew Osborne, as Chief Financial Officer, Lynette Herscha, as Chief Legal Officer, and Rajesh Beri, Ph.D., as Vice President of Process Development & Manufacturing Sciences.
Matthew Osborne, Chief Financial Officer
Matthew has more than 20 years of biotechnology industry and Wall Street experience with expertise in capital markets, strategic corporate finance and financial operations. Within industry, he led many equity financings for companies to fund through preclinical, clinical and commercial stages of development while driving the scientific, corporate and financial planning, communications and investor relations efforts. As a Wall Street equity biotechnology sell-side analyst, he launched several biotech IPOs and analyzed the development of several blockbuster drugs across many therapeutic areas and modalities. Mr. Osborne most recently served as Chief Financial Officer (CFO) of OncXerna Therapeutics and as CFO of Unum Therapeutics (now Cogent). Prior to Unum, he also served as VP of Corporate Affairs, Communications and Investor Relations at Voyager Therapeutics and Synageva BioPharma (acquired by Alexion), Global Head of Investor relations at Shire Plc (acquired by Takeda) and Investor Relations at Vertex Pharmaceuticals. Prior to his industry roles, Matthew served as a sell-side analyst covering the biotechnology sector at Lazard Capital Markets and Leerink Swann (SVB Leerink). He received an M.B.A. from the D'Amore-McKim School of Business at Northeastern University and a B.S. in Biology from Syracuse University.
Mr. Osborne commented, "Senda is pioneering a completely novel approach that leverages interspecies interactions within the human body to enable new categories of therapeutics. I am excited to join the Senda team to help advance this platform and programs with the potential to improve genetic and mRNA medicines, immuno-modulating therapeutics and novel small molecules."
Lynette Herscha, Chief Legal Officer
Lynette has more than 20 years of experience in various leadership roles in the technology and biopharma industry. Prior to joining Senda, she served as Chief Legal Officer for Solid Biosciences where she oversaw all aspects of Solid's legal affairs, including corporate governance, securities reporting, intellectual property and compliance. Prior to her tenure at Solid, she served as the General Counsel for Concert Pharmaceuticals, a company pioneering the use of deuterium chemistry to develop new medicines. Before joining Concert, Lynette held various senior legal positions at Momenta Pharmaceuticals, Inc., a public biotechnology company, and Phase Forward, Inc., a public technology company. She began her career at the law offices of Fulbright & Jaworski. Lynette holds a J.D. from Boston University School of Law and a B.A. from Boston University.
Rajesh Beri, Vice President of Process Development & Manufacturing Sciences
Rajesh has over 24 years of experience working in the biotech industry. His expertise is in process development, tech transfer, manufacturing sciences, and technology development. Rajesh has been involved in development and commercialization of 60 biologics derived from either mammalian or microbial cultures. He has made significant contributions to leading biologic products such as Enbrel®, Orencia®, Soliris®, Yervoy®, Opdivo® and Strensiq®. During his career he has held scientific and executive positions at Lonza, Amgen, GSK and Dow Chemicals. Rajesh received his Bachelor's degree from IIT, Mumbai, and his Doctorate degree in Chemical Engineering from Worcester Polytechnic Institute.
About Senda Biosciences
Senda is systematically harnessing the powerful molecular interactions that have evolved over millennia between humans, plants, and bacteria to develop new types of medicines. Senda's platform enables the deployment of proteins or genetic material throughout the body in unprecedented ways, tunable modulation of the immune system, and precise intervention at the point of interaction between human and non-human species. By pioneering this new approach, called intersystems biology, the company aims to develop novel medicines with unprecedented safety, efficacy, and precision. To learn more, please visit the company's website at www.sendabiosciences.com.
Source: Senda Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.